期刊文献+

泰拉菌素的合成工艺改进 被引量:3

Improvement of the Synthesis Process of Tulathromycin
下载PDF
导出
摘要 以阿奇霉素A(Ⅰ)为原料,经苄氧羰酰氯保护2'位羟基得到保护的阿奇霉素A(Ⅱ),然后经Albright-Goldman方法氧化4″位羟基得到Cbz保护的酮(Ⅲ),酮通过Wittig-Horner反应得到保护的烯(Ⅳ),烯经双氧水氧化得到保护的环氧化合物(Ⅴ),保护的环氧化合物在Pd/C催化下脱保护得到脱保护的环氧化合物(Ⅵ),脱保护的环氧化合物与正丙胺反应开环得到泰拉菌素粗品,粗品泰拉菌素成磷酸盐纯化,最后解析得到泰拉菌素(Ⅶ),总收率为42.0%,经HPLC测定w(Ⅶ)=98.0%。该法改进了文献合成方法,不需采用极低温反应。 Tulathromycin is a new-type macrolide antibiotic for animals. This study is intended to explore the improved synthetic process route for tulathromycin using azithromycin-A as the raw material. First, protective azithromycin-A was prepared by reaction of azithromycin-A with Cbz-C1 ; in this stage of reaction the second hydroxide of azithromycin-A was protected in the presence of Cbz-C1. Next, Cbz-protected ketone was prepared when the protective azithromycin-A was oxidized in the forth hydroxide by using Albright-Goldman method. Then, protective alkene was prepared in Witting-Horner reaction when ketone group converted alkenyl. And then Cbz-protected epoxy compound was prepared with protective alkene being oxidized in the presence of hydrogen peroxide. In the next step, deprotected epoxy compound was prepared with Cbz-protected epoxy compound deprotected by using Pd/C as catalyst. The crude product of tulathromycin was prepared by reaction of deprotected epoxy compound and propylamine. Finally, the crude product was purified by phosphate and then tulathromycin was obtained in a yield of 42.0% with a purity of 98.0% determined by HPLC. This study proposed a new and improved preparation route in which the reaction needn't be carried out at an extremely low temperature compared with previous methods. It can be effectively applied in industrial production.
出处 《精细化工》 EI CAS CSCD 北大核心 2012年第8期795-799,共5页 Fine Chemicals
基金 国家自然科学基金(20972123) 湖北省科技厅科技攻关项目(2011BBB075)~~
关键词 泰拉菌素 阿奇霉素A 工艺优化 医药与日化原料 tulathromycin azithromycin-A process optimization drug and cosmetic materials
  • 相关文献

参考文献10

  • 1亢继俊,王丽霞,曾振灵.动物专用大环内酯类新药——泰拉霉素[J].广东畜牧兽医科技,2010,35(2):7-10. 被引量:11
  • 2Sewell R C.Process for preparing 4″-substituted-9-deoxo-9a-aza-9a-homoerythromycin A derivatives[P].EP:1253153A1,2002-10-30.
  • 3Zhao Y,You Q D,Shen W B,et al.Design,synthesis,and anti-helicobacter polyfiactivity of erythromycin A(E)-9-oxime etherderivatives[J].Bioorg Med Chem Lett,2002,12:2771-2774.
  • 4Ma Zhen-kun,Clark R F,Antony B,el al.Novel erythromycinderivatives with aryl groups tethered to the C-6 position are potentprotein synthesis inhibitors and active against multidrug-resistantrespiratory pathogens[J].J Med Chem,2001,44(41):4137-4156.
  • 5Lindberg B,Slessor K N.Synthesis of 2'-O-benzoyl-3-keto-6-O-propargyl-11 12-carbamoyl erythromycin A[J].Acta Chem Scand,1967,21:910.
  • 6Paquette L A.Quantitative determination of the macrolide antibiotictulathromycin in plasma and bronchoalveolar cells of fouls usingtandem mss spectrometry[J].J Am Chem Soc,1989,111:5792.
  • 7Qiu Y L,Lytam P,Liu T Z,et al.11-12 Bicycileerythromycinderivatives[P].US:254126,2006-12-16.
  • 8Arai S,Hamaguchi S,Shioiri T,et al.Efficacy of tulathromycincompared with bovine respiratory disease[J].Tetrahedron Lett,1998,38:2997.
  • 9Sohani S,Deodhar M,Patcl N,et al.Process for the preparation oftelithromycin[P].WO:105821,2005-11-10.
  • 10Lyukina N S,Dolgina T M,Bondarenko G N,et al.Synthesis ofbiologically active 1-aryl-ethyl-phosphonates[J].Russian Journalof Organic Chemistry,2002,38(4):573-587.

二级参考文献15

  • 1宋福杰,刘明春,邹美,符特.兽用抗菌药物土拉霉素研究进展[J].兽药与饲料添加剂,2006,11(4):4-6. 被引量:8
  • 2Benchaoui H A, Nowakowski M, Sherington J, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine [J].Veterinary Pharmacol and Therapeutics[J].2004,27(4):203-210.
  • 3FDA. Freedom of Information Summary NADAI41-244[Z]. Date of Approval:December 28,2007.
  • 4Orhan Sahin, Paul J. Plummer, et al. Emergence of a Tetracycline-resistant Campylobacter jejuni Clo Associated with Outbreaks of Ovine Abortion in th United States[J].Journal of clinical Microbiology 2008,46(5):1663-1671.
  • 5Godinho K S. Susceptibility testing of tulathromycin interpretative Breakpoints andsusceptibility of field isolates[J].Veterinary Microbiology. 2008, 129(3-4):426-432.
  • 6Nowakowski, Inskeep, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, In cattle[J].Veterinary Therapeutics, 2004,5(1):60-74.
  • 7Eberhard Scheuch, Janina Spieker, Monica Venner, et al Quantitative determination of the macrolide antibiotic tulathromycin in plasma and bronchoalveolar cells of foals using tandem mass spectrometry[J]. Journal of Chromatography B, 2007,850:464-470.
  • 8Committee for Veterinary Medicinal Products Tulathromycin, Summary Report(2).European Medicines Agency Veterinary Medicines and Inspections[Z].EMEA/MRL/ 894/04-Final. 2004.
  • 9Nutsch R G, Hart F J, Rooney K A. Efficacy of tulathromyein injectable solution for the treatment of naturally occurring Swine respiratory disease [J]. Veterinary Therapeutics. 2005,6(2):214-24.
  • 10Robb E J, Tucker C M, Corley L, et al. Efficacy of tulathromycin or enrofloxacin for initial treatment of naturally occurring bovine respiratory disease in feeder calves[J].Veterinary Therapeutics. 2007, 8(2):127-135.

共引文献10

同被引文献80

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部